The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN is a #3 ...

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 4.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

BioMarin Pharmaceutical Inc. has a 52 week low of $60.63 and a 52 week high of $94.85. The business has a 50 day moving average price of $66.50 and a 200-day moving average price of $68.42.

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other top stock picks from Paul Singer’s latest portfolio. Stock markets are as ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as Palynziq in ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $126.00. The company’s shares ...

Disney is hosting a Hollywood premiere of “Snow White” on March 15, but the studio won’t be rolling out a robust red carpet like it usually does. The afternoon festivities will include a pre ...

Vanna White has become a beloved fixture on our screens over the years, turning over letters on the “Wheel of Fortune” board night after night for more than four decades. So, it may surprise ...